Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Healthcare Biotechnology
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Vaxil Bio Ltd
Bullboard Posts
User Avatar Image
(167)
•••
Comment by Jimpro63on Mar 28, 2020 11:18pm
189 Views
Post# 30856976

RE:RE:Vaxil Bio overachieving stated CoronaVirus Vaccine timelines

RE:RE:Vaxil Bio overachieving stated CoronaVirus Vaccine timelines
Jimpro63 wrote:

The purpose of my previous post, was to illustrate that News could be released sooner than you may expect here .  You have to make a decision in the near future if you want to invest in this legitimate Biotechnology Company or not .

Can any of the others state facts such as this :
Vaxil was founded by Weizmann Institute scientists, Israel’s top research university, in order to provide an altogether novel approach to immunotherapy. Vaxil has diligently advanced its immunotherapy platform and published its research and clinical results in top medical journals.
Vaxil currently holds 6 fully issued patents, with an additional 10 patents pending.
Vaxil Bio is listed by the World Health Organization as a Candidate to achieve a possible Vaccine for the Coronavirus. Now 11 Patents pending ( update )

This is the "Real Deal " here people



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities